Communication, HIV Treatment and Prevention Agents and Vaccines

Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention

Pharmaceutical Technology

JULY 2, 2025

How will RFK Jr’s American dream for vaccines play out? Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in the US, according to market analysts. Reports LOA and PTSR Model - GS-1720 in Human Immunodeficiency Virus (HIV).

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Packaging Communication Hospitals

Gilead hit with FDA clinical hold for batch of HIV trials

Pharmaceutical Technology

JUNE 11, 2025

The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Communication Hospitals Packaging

RX Note

FEBRUARY 23, 2023

Soft Contact Lenses - A basic overview Red Eye - Discussion on few possible conditions Styes - Warm compresses are the mainstay of treatment Eye Floaters - It is not often treated, except in severe cases.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy

Pharmacist Digest

Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention

Gilead hit with FDA clinical hold for batch of HIV trials

Contents

Stay Connected